Elevidys is a gene therapy for Duchenne muscular dystrophy in ambulatory boys aged 4–5 with confirmed mutations. Given as a single intravenous infusion, it delivers a shortened dystrophin gene to slow muscle decline. It offers a targeted option for eligible young patients, though it is not a cure.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends